Efficacy of somatostatin and its analogues in prevention of postoperative complications after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials.
OBJECTIVE
The aim of this study was to evaluate the efficacy of somatostatin and its analogues in prevention of postoperative complications after pancreaticoduodenectomy.


METHODS
A literature search of the MEDLINE, EMBASE, and Cochrane databases was used to identify randomized controlled trials that compared somatostatin and its analogues with control group after pancreaticoduodenectomy. Meta-analytical techniques were applied to identify differences in outcomes between the 2 groups.


RESULTS
A total of 8 studies were identified according to our inclusion criteria, including 2 studies using somatostatin, 5 studies using octreotide, and 1 study using vapreotide. The use of somatostatin or its analogues did not significantly benefit for reducing the incidence of pancreatic fistula (odds ratio [OR] 95% confidence interval [CI], 0.64-1.37; P = 0.73), total pancreas-specific postoperative complications (OR 95% CI, 0.63-1.42; P = 0.79), delayed gastric emptying (OR 95% CI, 0.50-1.78; P = 0.86), total complication (OR 95% CI, 0.73-1.70; P = 0.61), mortality (OR 95% CI, 0.59-7.72; P = 0.97), and length of postoperative hospital stay (weighted mean difference 95% CI, -7.74 to 4.47; P = 0.60).


CONCLUSIONS
The use of somatostatin and its analogues does not significantly reduce postoperative complications after pan-creaticoduodenectomy.
Zeng
Qiqiang
Q
Department of General Surgery, First Affiliated Hospital, Wenzhou Medical College, Wenzhou, Zhejiang Province, China.
Zhang
Qiyu
Q
Han
Shaoliang
S
Yu
Zhengping
Z
Zheng
Minghua
M
Zhou
Mengtao
M
Bai
Jianling
J
Jin
Rong
R
D005746:Gastric Emptying; D006801:Humans; D007902:Length of Stay; D016239:MEDLINE; D015282:Octreotide / Q000627:therapeutic use; D010185:Pancreatic Fistula / Q000453:epidemiology / Q000517:prevention & control; D016577:Pancreaticoduodenectomy / Q000009:adverse effects* / Q000401:mortality; D011183:Postoperative Complications / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use*
C051458:vapreotide; D013004:Somatostatin; D015282:Octreotide